Patent: 10,039,810
✉ Email this page to a colleague
Summary for Patent: 10,039,810
Title: | Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies |
Abstract: | Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract. |
Inventor(s): | Morales; Mercedes (San Francisco, CA), Imran; Mir (Los Altos Hills, CA), Korupolu; Radhika (Fremont, CA), Hashim; Mir (Fremont, CA) |
Assignee: | InCube Labs, LLC (San Jose, CA) |
Application Number: | 14/714,136 |
Patent Claims: | see list of patent claims |
Details for Patent 10,039,810
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | Injection | 125504 | 01/21/2015 | ⤷ Try a Trial | 2034-05-15 |
Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | For Injection | 125504 | 01/21/2015 | ⤷ Try a Trial | 2034-05-15 |
Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | Injection | 125504 | 05/28/2021 | ⤷ Try a Trial | 2034-05-15 |
Eli Lilly And Company | TALTZ | ixekizumab | Injection | 125521 | 03/22/2016 | ⤷ Try a Trial | 2034-05-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |